Want to see MYO full AI Analyst Report?
MYO Stock Chart & Stats
$0.86
-$0.13(-1.86%)
At close: 4:00 PM EST
$0.86
-$0.13(-1.86%)
Day’s Range― - ―
52-Week Range$0.61 - $2.22
Previous CloseN/A
Volume192.17K
Average Volume (3M)1.13M
Market Cap
$40.57M
Enterprise Value$31.82
Total Cash (Recent Filing)$15.70M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding38,638,653
10 Day Avg. Volume332,287
30 Day Avg. Volume1,127,050
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside510.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$44.43M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth With Healthy Unit EconomicsMulti-year revenue growth (~69% TTM) paired with durable gross margins (~66% TTM, Q1 at ~68%) indicates sound unit economics. This combination supports scalable revenue expansion and provides a buffer for reinvesting in distribution and R&D while pursuing margin improvements over the next several quarters.
Shift Toward Recurring Revenue And Improved Payor AccessThe move from one-time direct sales to recurring patient sources (49% of Q1 revenue vs 25% prior year) plus materially expanded payer access (covered lives up to 158M, national Elevance arrangement) increases revenue predictability, authorization rates and long-term patient lifetime value.
Product & Channel Improvements That Lower Unit CostsA ~10% material-cost reduction from the new app, continued product development (MyoPro 3) and an RCT build clinical evidence, while strong international and O&P channel growth diversifies revenue. Together these structural moves support sustainable margin gains and broader market access.
Bears Say
Negative Operating And Free Cash FlowPersistent negative OCF and FCF at material magnitudes (~-$14M and ~$-17M TTM) mean the company is burning cash despite revenue gains. This constrains strategic flexibility, requires ongoing external funding, and elevates dilution or financing risk until cash generation turns positive.
Elevated Leverage And Stressed Balance SheetA step-up in leverage in 2025 (debt/equity to ~1.70) even after partial improvement (≈0.89 TTM) tightens financial flexibility. Elevated leverage increases interest and covenant sensitivity and raises the probability of further capital raises if operating cash flow does not improve.
Sustained Unprofitability And Negative MarginsDespite revenue and gross-margin progress, the company remains deeply unprofitable (TTM net margin ~-37%, negative adjusted EBITDA). This signals limited operating leverage to date; sustained losses require meaningful margin expansion or cost control to reach self-funded growth.
Myomo News
MYO FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was $0.60 and its highest was $2.22 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is $40.57M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Aug 11, 2026 which is in 25 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on May 07, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.044.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.1.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 38,638,653 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -5.052%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in MYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.25 (510.47% Upside)
$5.25 (510.47% Upside)
Blogger Sentiment
Bullish
MYO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 62.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $207.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.15%
12-Months-Change
Fundamentals
Return on Equity
-114.87%
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
MYO Stock 12 Month Forecast
Average Price Target
$5.25
▲(510.47% Upside)
Technical Analysis
Ownership Overview
8.93% Insiders
5.61% Mutual Funds
0.42% Other Institutional Investors
80.86% Public Companies and
Individual Investors